|Articles|November 8, 2022
- Pharmaceutical Executive-11-01-2022
- Volume 42
- Issue 11
Pharmaceutical Executive, November 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
A Culture of Quality: The Catalyst to Accelerate Innovationover 3 years ago
A Mission of the Heartover 3 years ago
The New Reality for Industry Dealmaking May be Setting Inover 3 years ago
Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?over 3 years ago
Digital Biomarkers Could Reshape CNS Diagnosis, Treatmentover 3 years ago
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?over 3 years ago
Recaps, Live & In Personover 3 years ago
FDA Keeps Its User Fees, but Fails to Gain Important ReformsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Keytruda-Based Regimen for PD-L1–Positive Platinum-Resistant Ovarian Cancer
2
FDA Sends Refusal-to-File Letter to Moderna for Seasonal Influenza Vaccine, Enters Long-Term Agreement with Government of Mexico
3
Today’s China Crucible: What It Means for Pharma
4
Sanofi Appoints Belén Garijo as Chief Executive Officer
5